Title:
METHOD FOR PREDICTING THERAPEUTIC EFFECTS OF IRINOTECAN, AND KIT FOR SAME
Document Type and Number:
WIPO Patent Application WO/2018/235937
Kind Code:
A1
Abstract:
The present invention predicts the therapeutic effects of irinotecan using a prescribed genetic polymorphism. According to the present invention, the genetic polymorphism specified by rs1980576 in the APCDD1L gene or a genetic polymorphism in linkage disequilibrium with the abovementioned genetic polymorphism is analyzed, and a determination is made on the basis of the genotype of the abovementioned genetic polymorphism.
Inventors:
TSUNEDOMI RYOUICHI (JP)
HAZAMA SHOICHI (JP)
NAGANO HIROAKI (JP)
HAZAMA SHOICHI (JP)
NAGANO HIROAKI (JP)
Application Number:
PCT/JP2018/023773
Publication Date:
December 27, 2018
Filing Date:
June 22, 2018
Export Citation:
Assignee:
UNIV YAMAGUCHI (JP)
TOYO KOHAN CO LTD (JP)
TOYO KOHAN CO LTD (JP)
International Classes:
C12Q1/68; C12N15/09; C12Q1/6876
Domestic Patent References:
| WO2016132736A1 | 2016-08-25 | |||
| WO2011152272A1 | 2011-12-08 | |||
| WO2010025952A1 | 2010-03-11 | |||
| WO2010124239A2 | 2010-10-28 | |||
| WO2010103851A1 | 2010-09-16 | |||
| WO2016132736A1 | 2016-08-25 |
Foreign References:
| JP2008072913A | 2008-04-03 | |||
| JP2017122569A | 2017-07-13 | |||
| JP2016000793W | 2016-02-16 | |||
| JP2011250726A | 2011-12-15 |
Other References:
HAN, JY. ET AL.: "Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer", CANCER, vol. 110, no. 1, 2007, pages 138 - 147, XP002688160, ISSN: 0008-543X
LIU, CY . ET AL.: "UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma", CANCER, vol. 112, no. 9, 2008, pages 1932 - 1940, XP055564712
HAZAMA, SHOICHI ET AL.: "Effects of anticancer agent and current status of side-effect prediction method: CPT-11 (Irinotecan", JAPANESE JOURNAL OF CANCER AND CHEMOTHERAPY, vol. 35, no. 2, 2008, pages 182 - 184, XP009518218, ISSN: 0385-0684
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 136572-09-3
"NCBI", Database accession no. NM 153360.1
"Molecular Biology", 1989, JOHN WILEY & SONS, pages: 6.3.1 - 6.3.6
WANG ET AL., NUCLEIC ACIDS RES., vol. 34, 2014, pages 195 - 201
See also references of EP 3643791A4
LIU, CY . ET AL.: "UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma", CANCER, vol. 112, no. 9, 2008, pages 1932 - 1940, XP055564712
HAZAMA, SHOICHI ET AL.: "Effects of anticancer agent and current status of side-effect prediction method: CPT-11 (Irinotecan", JAPANESE JOURNAL OF CANCER AND CHEMOTHERAPY, vol. 35, no. 2, 2008, pages 182 - 184, XP009518218, ISSN: 0385-0684
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 136572-09-3
"NCBI", Database accession no. NM 153360.1
"Molecular Biology", 1989, JOHN WILEY & SONS, pages: 6.3.1 - 6.3.6
WANG ET AL., NUCLEIC ACIDS RES., vol. 34, 2014, pages 195 - 201
See also references of EP 3643791A4
Attorney, Agent or Firm:
HIRAKI & ASSOCIATES (JP)
Download PDF: